Arterial Healing is a Journey
We’re at each step of your patient’s healing journey
Not all polymers are the same

Specifically Designed Polymer

- Biosensors’ PLA polymer degrades to naturally occurring lactate over a 9-month period.
- Faster polymer degradation may not be optimal for wound healing.
- Lactate plays a key role in local wound healing processes, mainly via enhanced VEGF production.

The localized presence of PLA-derived lactate has the potential to facilitate arterial wound healing, including re-endothelialization.

Biosensors’ Proprietary Limus Drug

- Biolimus A9™ (BA9™) is highly lipophilic versus other common limus drugs, with greater local bioavailability.
- BA9 exerts localized anti-inflammatory and anti-proliferative effects, reducing the risk of excessive neointimal thickening and restenosis.

BA9 elution time from the BIOMATRIX FAMILY of DES of at least six months ensures continuous anti-restenotic therapy for as long as the patient needs.

The BIOMATRIX FAMILY is tailored to cover the healing journey of your patients.

In vivo Presence of BA9 and Biodegradation of PLA with Wound Healing Cascade Overlay

- I - Haemostasis
- II - Inflammation
- III - Proliferation
- IV - Remodelling & Scar Formation

Residual BA9 in Tissue (µg)

100%
80%
60%
40%
20%
0%

Log (Time)

Residual BA9 in Tissue (µg)

PLA Mass (µg)

6 months
9 months

† Pharmacokinetic data for BA9-eluting stent with biodegradable PLA polymer, derived from porcine models.

Bridging science and innovative technology for optimised arterial healing

The BIOMATRIX FAMILY favourably influences local wound healing processes.

The BIOMATRIX FAMILY is tailored to cover the healing journey of your patients.
Designed to match the wound healing journey of real-world patients

The BIOMATRIX FAMILY offers added reassurance for a wide range of patient profiles, including potentially slow healers.

- Every patient heals differently and it’s not always possible to predict how long a particular patient will need anti-restenotic therapy.
- Available data suggest that many DES-related lesions are likely to take more than 3 to 4 months to heal completely.9,12

Efficacy extends to patients with severe CAD (e.g. ACS, multi-vessel disease, etc.), as well as individuals with diabetes.15,18

### Predictors of slower wound healing include:13-16

- More severe CAD (e.g. ACS vs stable CAD)
- Chronic disease (e.g. PVD, cancer, diabetes)
- Immunocompromising conditions
- Older age
- Certain medications (e.g. glucocorticoids, NSAIDs, chemotherapy)
- Poor nutritional status
- Obesity
- Smoking & alcoholism

### Proven broad-spectrum efficacy17-19

Efficacy extends to patients with severe CAD (e.g. ACS, multi-vessel disease, etc.), as well as individuals with diabetes.15,18

### Localised anti-restenotic therapy for at least six months*  

Outcomes in complex patients across clinical studies

<table>
<thead>
<tr>
<th>ALL-COMERS</th>
<th>STEMI</th>
<th>STEMI</th>
<th>STEMI</th>
<th>IDDM</th>
<th>CTO</th>
<th>SYNTAX</th>
</tr>
</thead>
<tbody>
<tr>
<td>POCE (%)</td>
<td>(%)</td>
<td>(%)</td>
<td>(%)</td>
<td>(%)</td>
<td>(%)</td>
<td>(%)</td>
</tr>
<tr>
<td>CD+MACE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RR (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data from LEADERS study; an ‘all-comers’ study, in which patients with stable CAD or an ACS were randomized to receive either a BIOMATRIX stent (n=857) or a sirolimus-eluting stent (SES, with durable polymer; n=850).17,18

Data from the COMFORTABLE AMI study, in which 1161 patients with ST-segment-elevation MI and undergoing primary PCI were randomized to receive either a BIOMATRIX stent or a bare metal stent.19
The preferred choice of DES for your patients

Many DES-related vessel lesions take more than 3 to 4 months to completely heal\textsuperscript{9,12}

The BIOMATRIX FAMILY favourably influences local wound healing processes

\begin{itemize}
  \item Highly localised delivery of anti-restenotic BA9™ for at least six months\textsuperscript{1-4}
  \item Degradation of specifically designed PLA polymer to lactate, which has the potential to facilitate wound healing\textsuperscript{2,6,7}
\end{itemize}

The BIOMATRIX FAMILY has proven efficacy in a broad range of patient types, including complex patients\textsuperscript{17-19}

We’re with your patients from start to finish


LEADERS is a Biosensors International study. www.clinicaltrial.gov - NCT00389220. BioMatrix, Biolimus A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd. All other cited trademarks are the property of their respective owners.

Not available for sale in the United States and certain other countries.

© 2015 Biosensors International Group, Ltd. All rights reserved

www.biosensors.com